Quest's $344M Celera Buy Averts Antitrust Hurdle
Quest Diagnostics Inc.'s planned $344 million purchase of genetic research and development company Celera Corp. took a step toward completion Wednesday with the expiration of a statutory waiting period for antitrust...To view the full article, register now.
Already a subscriber? Click here to view full article